Xanodyne Pharmaceuticals, Inc., anintegrated specialty pharmaceutical company with both development andcommercial capabilities focused on women's healthcare and pain management,announced today that the U.S. launch of Zipsor(TM) (diclofenac potassium)Liquid Filled Capsules, is now underway and being supported by an expanded250-member specialty sales force.
In June 2009, Xanodyne received Food and Drug Administration (FDA)approval for Zipsor, a new treatment option for relief of mild to moderateacute pain in adults (18 years of age or older). With the national launch ofZipsor, Xanodyne has now successfully executed on two key elements of itsbusiness model - R&D and commercialization.
Commenting on the launch, Natasha Giordano, Chief Commercial Officer,said, "The launch of Zipsor was a tremendous achievement for Xanodyne. Within90 days of receiving FDA approval, we were able to scale up our commercialorganization and secure broad distribution at retail pharmacies for theproduct."
Giordano added, "This is an exciting time for Xanodyne as we seek to gaina foothold in the pain marketplace with Zipsor. Our newly expanded team ofexperienced sales representatives enables Xanodyne to achieve a greatergeographic reach and frequency of product details to healthcare professionalsacross the United States."
Xanodyne remains committed to aggressively executing its productcommercialization strategy for its emerging product portfolio. The companyexpects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamicacid compound under priority review for the potential treatment of womensuffering from heavy menstrual bleeding.